Update of Metastatic Surveillance of Uveal Melanoma
Melanoma Focus have set up a Guideline Development Group (GDG) to update the metastatic surveillance of Uveal Melanoma guideline which was originally published in 2015. This work commenced in September 2022 and the consultation will be open until 1st June 2023.
The Guideline Development Group (GDG) will be led by Dr Matthew Wheater, with project management and methodological support by Nancy Turnbull and funding by Melanoma Focus.
The Guideline Development Group consists of:
- Dr Matthew Wheater, Medical Oncologist
- Mrs Nancy Turnbull, Project Manager
- Professor Sarah Coupland, Histopathologist
- Professor Bertil Damato, Ophthalmologist
- Mr Stephen Fenwick, Hepatobiliary surgeon
- Dr Leila Khoja, Medical Oncologist
- Dr Sachin Modi, Interventional Radiologist
- Mr Guy Negretti, Ophthalmologist
- Dr Heather Shaw, Medical Oncologist
- Ms Reta Sowton, Oncology Nurse
- Ms Helen Evans, Patient Representative
- Ms Tracey Krausa, Patient Representative
Consultation- Uveal melanoma surveillance update
The chair of the uveal surveillance update, Dr Matthew Wheater, invites you to comment on the guidance and executive summary.
The final guideline will be included in the 2022 Uveal Melanoma Update available on the Melanoma Focus website.
When making comments please remember that this guidance addresses surveillance only. No changes can be made to the rest of the guidance at this time as it has been signed off and published. The full guidelines will next be reviewed in five years’ time as per methodology agreed with NICE.
Draft Executive Summary- We are particularly interested in your views on the recommendations in this document. If, for example, you think the evidence has been misinterpreted or if higher quality evidence has been overlooked please note this on the Comments table. In the absence of evidence, recommendations were made after debate by the Guideline Development Group (GDG) and we would welcome your views on these.
Draft Full Guidance-The available evidence has been searched and reviewed. The evidence reviews and the decisions made by the GDG which underpin the recommendations are detailed in the full document. The full guideline also contains the recommendations, -please comment on them only once. Changes made to recommendations in either document will be reflected in the other.
Draft Appendix- contain more detailed tables and supporting information.
Comments table-Please put your name on the table and put all of your comments into this table noting page number and recommendation number. We do not have the resources to deal with comments received in any other format.
How to comment
Please use document 5 the comments table for all your comments. For each comment put the page number in the first column and either the recommendation number, for the executive summary, or the line number in the second column. This is very important.
Page 1 is for comments on document 1 – the Executive Summary
Page 2 for comments on document 2 – the full guideline
Page 3 for comments on the Appendix
Please add extra lines and pages as needed.
The recommendations are in both document 1 or 2, please comment in one or the other, there is no need to comment in both.
We would be grateful if you would return the Comments table as soon as possible by 1st June at the latest to the Nancy Turnbull, the Project Manager, at email@example.com
We would like comments from a wide range of people with experience of this condition, as a patient/carer, support group or as a clinician, and would be grateful if you would forward this email to anyone who you think may be interested.
Please Note: In the interests of transparency, comments are not anonymous. Names will be published with the comments and the Development Group response on the Melanoma Focus Website at the time of publication of the guideline. We will ask for declarations of interest from all reviewers.
Thank you for your interest and help. Your contribution will be acknowledged in the guideline.